Currently Viewing:
COA Community Oncology Conference 2019
COA Close to Filing OCM 2.0 for Federal Review
April 05, 2019
Strategies for Fighting Consolidation in Community Oncology
April 05, 2019
Katie Goodman: Bring Clinical Trials to the Community Setting to Meet Patients Where They Are
April 05, 2019
Dr Howard Burris on Efforts Needed to Ensure Access to NGS Testing
April 05, 2019
Dr Lee Schwartzberg Explains the Promise of Liquid Biopsies in Cancer
April 06, 2019
Dr C.K. Wang Discusses How Real-World Data Can Benefit Payers
April 06, 2019
Pharma Discusses How to Reframe Value in Era of Precision Medicine, Combinations
April 06, 2019
Step Therapy in Medicare Advantage Hurts Patients, Providers, Says Schwartzberg
April 06, 2019
Currently Reading
Dr Basit Chaudhry Outlines Findings From OCM PP3
April 07, 2019
Dr Jeff Patton on OCM PP3 Results, Challenges With the Model
April 09, 2019
Dr Sonia T. Oskouei Discusses Uptake, Cost Savings With Filgrastim Biosimilar Xarzio
April 11, 2019
Katie Goodman on FDA's Efforts to Expand Patient Inclusion Criteria for Clinical Trials
April 11, 2019
Dr Lee Schwartzberg Reflects on the Approval of the First Immunotherapy Regimen in Breast Cancer
April 12, 2019
Dr C.K. Wang on How Real-World Data Provide a More Comprehensive Picture of Drug Efficacy
April 14, 2019
Dr Basit Chaudhry on Challenges With Improving Performance Under OCM
April 17, 2019
Dr Jeff Patton Explains How Physician Shortage, Burnout Are Impacting Community Oncologists
April 22, 2019
Dr Lee Schwartzberg on Genetic Testing for All Patients Diagnosed With Breast Cancer
April 23, 2019
Dr Sonia Oskouei Explains the Importance of Education Around Biosimilars
April 24, 2019
Katie Goodman Discusses Clinical Trial Participation Criteria's Impact on Trial Participation
April 25, 2019
Dr C.K. Wang: How COTA's Real-World Data Platform Helps Oncologists Make Informed Decisions
April 27, 2019
What Dr Howard Burris Will Focus on as ASCO President
April 28, 2019
Dr Basit Chaudhry: Evaluating the Adequacy of Novel Therapy Adjustment Under OCM
April 29, 2019
Dr Lee Schwartzberg Outlines Challenges With Accessing Multigene Testing in the Community Setting
May 07, 2019
Dr Jeff Patton Discusses CMS' Proposal to Ease Protections on 6 Drug Classes in Part D
May 08, 2019

Dr Basit Chaudhry Outlines Findings From OCM PP3

Results from performance period 3 (PP3) were somewhat concerning because the amount of practices that achieved a shared savings stayed stable from PP2, explained Basit Chaudhry, MD, PhD, founder of Tuple Health.

Results from performance period 3 (PP3) were somewhat concerning because the amount of practices that achieved a shared savings stayed stable from PP2, explained Basit Chaudhry, MD, PhD, founder of Tuple Health.


With results from OCM performance period 3 now out, did you see improvement over performance periods 2 and 1?

It’s interesting. In PP3, 33% of practices were able to achieve a shared savings. I think that was somewhat concerning because that’s stayed stable since PP2. So, in PP2, there was also 33% of practices that achieved a savings. In PP1, it had been 25%. So, between PP1 and PP2, we saw a growth or improvement. I personally was hoping that we’d continue to see aggregate improvement in performance in terms of achieving a shared savings. That unfortunately didn’t happen, so that aspect of performance leveled out.

The other thing that was important about the results that we saw from PP3 is that we’ve gotten additional data on what’s happened in the true-up period. So, true-ups are roughly, Medicare claims can be sent in about a year after a service is provided. So, in performance-based models, you continue to look at what happens as claims roll out or into Medicare. So, for PP1, the number of practices that retained a shared savings went from 25% to 20%. For PP2, it went from 33% to 25%. So, there’s kind of 2 trends I think that are concerning with the results of shared savings. One is we’ve leveled out in terms of the proportion of practices that have achieved a shared savings, and then the true-up process, we’re seeing a regression of the results.

Now, from what we understand from Medicare, different practices are getting shared savings at different times. So, overall from what they’ve said is that from the start of the program, around 50% of all the participants have achieved at least 1 shared savings. So, I feel like that’s progress in certain respects, but in aggregate, I think there’s still concerns over where practices are. The other thing I think is sort of how do you look at performance versus the benchmark. So, the benchmark doesn’t take into account the amount that’s provided from the MEOS [Monthly Enhanced Oncology Services] payments or the 4% discount, which is supposed to neutralize that. So, practices are doing better with respect to the benchmark; about three quarters of practices, from what we understand, are under benchmark. But, there’s still a concern there on how people are doing with respect to performance-based payments, and what this means is the upshot of it is that if practices are going to stay in OCM, a good proportion most likely would need to go to a down-sided risk model.

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up